Jeff Jones
Stock Analyst at Oppenheimer
(4.12)
# 1,637
Out of 5,096 analysts
289
Total ratings
34.1%
Success rate
8.8%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Reiterated: Buy | $50 → $25 | $14.87 | +68.12% | 10 | Oct 26, 2026 | |
| ODTX Odyssey Therapeutics | Reiterated: Buy | $40 | $19.54 | +104.71% | 3 | Oct 21, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $40 | $15.93 | +151.10% | 1 | Sep 9, 2026 | |
| PHVS Pharvaris | Reiterated: Buy | $50 → $75 | $33.53 | +123.68% | 12 | Sep 8, 2026 | |
| ALMS Alumis | Reiterated: Buy | $55 → $37 | $6.73 | +449.78% | 16 | Sep 2, 2026 | |
| PMVP PMV Pharmaceuticals | Reiterated: Buy | $5 | $1.31 | +281.68% | 18 | Sep 1, 2026 | |
| AAPG Ascentage Pharma Group International | Reiterated: Buy | $45 | $14.46 | +211.28% | 2 | Aug 21, 2026 | |
| MDWD MediWound | Reiterated: Buy | $32 → $30 | $13.30 | +125.56% | 6 | Aug 14, 2026 | |
| PTHS Pelthos Therapeutics | Reiterated: Buy | $66 → $64 | $9.40 | +580.85% | 9 | Aug 14, 2026 | |
| ACRV Acrivon Therapeutics | Reiterated: Buy | $8 | $1.66 | +381.93% | 2 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $1.15 | +1,030.43% | 32 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $48 | $4.22 | +1,037.44% | 24 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $10.03 | +229.01% | 18 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $11 | $3.66 | +200.55% | 1 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $1.16 | +2,055.17% | 22 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.97 | +151.89% | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $41 → $40 | $12.23 | +227.06% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $7 | $3.24 | +116.05% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $86 | $30.49 | +182.06% | 7 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.21 | - | 20 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $126.63 | -5.24% | 12 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $16 | $4.04 | n/a | 4 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $20 | $4.35 | n/a | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.8589 | n/a | 22 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.77 | n/a | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.53 | n/a | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.90 | n/a | 5 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.90 | n/a | 4 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $2.93 | n/a | 3 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | n/a | 2 | Jul 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.0111 | n/a | 1 | Sep 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $46.12 | n/a | 1 | Jun 22, 2021 |
ArriVent BioPharma
Oct 26, 2026
Reiterated: Buy
Price Target: $50 → $25
Current: $14.87
Upside: +68.12%
Odyssey Therapeutics
Oct 21, 2026
Reiterated: Buy
Price Target: $40
Current: $19.54
Upside: +104.71%
Aktis Oncology
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $15.93
Upside: +151.10%
Pharvaris
Sep 8, 2026
Reiterated: Buy
Price Target: $50 → $75
Current: $33.53
Upside: +123.68%
Alumis
Sep 2, 2026
Reiterated: Buy
Price Target: $55 → $37
Current: $6.73
Upside: +449.78%
PMV Pharmaceuticals
Sep 1, 2026
Reiterated: Buy
Price Target: $5
Current: $1.31
Upside: +281.68%
Ascentage Pharma Group International
Aug 21, 2026
Reiterated: Buy
Price Target: $45
Current: $14.46
Upside: +211.28%
MediWound
Aug 14, 2026
Reiterated: Buy
Price Target: $32 → $30
Current: $13.30
Upside: +125.56%
Pelthos Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $66 → $64
Current: $9.40
Upside: +580.85%
Acrivon Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $8
Current: $1.66
Upside: +381.93%
Aug 11, 2026
Reiterated: Buy
Price Target: $13
Current: $1.15
Upside: +1,030.43%
Aug 7, 2026
Reiterated: Buy
Price Target: $52 → $48
Current: $4.22
Upside: +1,037.44%
Aug 7, 2026
Reiterated: Buy
Price Target: $33
Current: $10.03
Upside: +229.01%
Jul 31, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $3.66
Upside: +200.55%
May 15, 2026
Reiterated: Buy
Price Target: $25
Current: $1.16
Upside: +2,055.17%
May 8, 2026
Reiterated: Buy
Price Target: $10
Current: $3.97
Upside: +151.89%
May 8, 2026
Reiterated: Buy
Price Target: $41 → $40
Current: $12.23
Upside: +227.06%
May 8, 2026
Reiterated: Buy
Price Target: $6 → $7
Current: $3.24
Upside: +116.05%
Apr 20, 2026
Reiterated: Buy
Price Target: $86
Current: $30.49
Upside: +182.06%
Mar 2, 2026
Rated: Hold
Price Target: n/a
Current: $1.21
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $120
Current: $126.63
Upside: -5.24%
Aug 15, 2025
Reiterated: Buy
Price Target: $17 → $16
Current: $4.04
Upside: n/a
Aug 14, 2025
Reiterated: Buy
Price Target: $19 → $20
Current: $4.35
Upside: n/a
Aug 8, 2025
Reiterated: Hold
Price Target: n/a
Current: $0.8589
Upside: n/a
Oct 29, 2024
Rated: Hold
Price Target: n/a
Current: $1.77
Upside: n/a
Aug 14, 2024
Reiterated: Hold
Price Target: n/a
Current: $4.53
Upside: n/a
Nov 30, 2023
Reiterated: Buy
Price Target: n/a
Current: $7.90
Upside: n/a
Nov 7, 2023
Reiterated: Buy
Price Target: n/a
Current: $0.90
Upside: n/a
Apr 28, 2023
Rated: Buy
Price Target: n/a
Current: $2.93
Upside: n/a
Jul 20, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Sep 30, 2021
Reiterated: Hold
Price Target: n/a
Current: $0.0111
Upside: n/a
Jun 22, 2021
Reiterated: Buy
Price Target: $37
Current: $46.12
Upside: n/a